雌激素替代疗法降低全关节置换术后静脉血栓栓塞及相关内科并发症风险
基于2015至2020年全国数据库的回顾性研究,纳入893759例初次全髋关节置换和1660909例全膝关节置换。经倾向性匹配后,术前90天内使用雌激素替代疗法(ERT)的全髋置换患者深静脉血栓风险降低(OR 0.52),全膝置换患者深静脉血栓、肺栓塞及内科并发症风险均降低,全髋置换肺栓塞无显著差异。
要点
- 全髋置换中ERT与深静脉血栓风险降低相关(OR 0.52,95%CI 0.29至0.91,P=0.028),肺栓塞无显著差异。
- 全膝置换中ERT与深静脉血栓(OR 0.60)、肺栓塞(OR 0.56)及内科并发症(OR 0.53)风险降低相关。
- 全髋置换中ERT组内科并发症风险低于对照组(OR 0.47,95%CI 0.31至0.73,P<0.001)。
核心结论
- 全关节置换术中使用的ERT与静脉血栓栓塞及术后主要内科并发症风险降低相关。
- 作者认为在就全关节置换术期间ERT管理对患者进行咨询时,应考虑这些发现。
研究设计与样本
- 回顾性研究,查询大型全国数据库的国际疾病分类第十版手术操作代码。
- 2015年至2020年间共识别893759例初次全髋关节置换和1660909例全膝关节置换。
- 全髋置换中3425例(3.5%)术前90天内处方ERT,按年龄、吸烟、肥胖和糖尿病诊断倾向性匹配至6850例对照。
- 全膝置换中7409例(3.5%)处方ERT,同样倾向性匹配至14818例对照。
主要发现
- 倾向性匹配后,全髋置换中ERT组深静脉血栓风险低于对照组(OR 0.52,95%CI 0.29至0.91,P=0.028)。
- 全髋置换中ERT组与对照组肺栓塞无显著差异(OR 0.67,95%CI 0.34至1.32,P=0.31)。
- 全髋置换中ERT组内科并发症风险低于对照组(OR 0.47,95%CI 0.31至0.73,P<0.001)。
- 全膝置换中ERT组深静脉血栓风险低于对照组(OR 0.60,95%CI 0.44至0.82,P=0.001)。
- 全膝置换中ERT组肺栓塞风险低于对照组(OR 0.56,95%CI 0.37至0.83,P=0.005),内科并发症风险亦低于对照组(OR 0.53,95%CI 0.42至0.67,P<0.001)。
临床怎么用
- 作者认为,在就全关节置换术期间ERT管理对患者进行咨询时,应考虑这些发现。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Estrogen replacement therapy (ERT) and total joint arthroplasty (TJA) are prevalent in the geriatric population, with limited evidence for how ERT influences postoperative outcomes. ERT is often held before arthroplasty due to the perceived risk for venous thromboembolism (VTE). Our primary aim was to investigate the relationship between ERT and VTE risk and secondarily to investigate major medical complications following TJA. METHODS: A retrospective review was performed with a large national database querying International Classification of Diseases, tenth revision procedure codes, identifying 893,759 primary total hip arthroplasty (THA) and 1,660,909 total knee arthroplasty (TKA) procedures from 2015 to 2020. Of THAs, a cohort of 3,425 (3.5%) were prescribed ERT within 90 days before surgery and propensity matched to 6,850 control patients for age, tobacco use, obesity, and diabetes diagnosis. Of TKAs, a cohort of 7,409 (3.5%) was prescribed ERT and similarly propensity matched to 14,818 control patients. Propensity-matched data were qualified with adjusted odds ratios (OR) and 95% confidence intervals (CI) for deep vein thrombosis (DVT), pulmonary embolism (PE), and total medical complications. RESULTS: After propensity matching, ERT use in THA demonstrated decreased risk of DVT (OR 0.52, CI 0.29 to 0.91, P = 0.028) but no difference in PE (OR 0.67, CI 0.34 to 1.32, P = 0.31). The ERT cohort had lower medical complications (OR 0.47, CI 0.31 to 0.73, P < 0.001). Among TKAs, ERT use was associated with decreased risk of DVT (OR 0.60, CI 0.44 to 0.82, P = 0.001), PE (OR 0.56, CI 0.37 to 0.83, P = 0.005), and medical complications (OR 0.53, CI 0.42 to 0.67, P < 0.001). CONCLUSIONS: The use of ERT with TJA is associated with decreased risk of VTE and major medical postoperative complications. These findings should be considered when counseling patients regarding the management of ERT when undergoing TJA.
引用
- Zhao S, Kelly M, Smith S, et al. Estrogen Replacement Therapy Decreases Associated Risk of Postoperative Venous Thromboemboli and Medical Complications After Total Joint Arthroplasty. J Arthroplasty. 2025. PMID: 40379114. doi:10.1016/j.arth.2025.05.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。